FLT3 and acute myeloid leukemia: Despite recent advances in the treatment of AML, the long-term survival rate is unacceptably low and new therapeutic strategies are urgently needed for patients, particularly those who cannot undergo transplantation and exhibit high-risk molecular profiles regarding relapse, such as the FLT3-ITD+ subset of AML.